医学
工作队
老年肿瘤学
任务(项目管理)
内科学
肿瘤科
癌症治疗
老年学
癌症
家庭医学
管理
公共行政
政治学
经济
作者
Rupert Bartsch,Daniel Aletaha,Thorsten Fuereder,Matti Aapro,François R. Jornayvaz,Pierre Olivier Lang,Denis Migliorini,Chantal Csajka,Marie‐Bernadette Aretin,Vérène Dougoud-Chauvin
标识
DOI:10.1016/j.jgo.2024.102077
摘要
Corticosteroids are used frequently in oncology and many patients require short- or long-term corticosteroid therapy. General clinical guidelines and recommendations exist on the use of corticosteroids; however, evidence is lacking for recommendations on their appropriate use in older adult with cancer. Treatment of chemotherapy-induced nausea and vomiting (CINV) has dramatically improved over the last decade with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists and neurokinin-1 (NK-1) receptor antagonists or a combination of both. However, corticosteroids continue to play an important role in the management of acute and delayed CINV prevention. While highly efficacious, the toxicity profile of corticosteroids must be considered, particularly in heterogeneous older patients with multiple comorbidities and polypharmacy. Guidance on corticosteroid-reducing/sparing strategies in this specific population is needed. This consensus, supported by the International Society of Geriatric Oncology, aims to provide evidence-based recommendations for the use of corticosteroid therapy in older adults with cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI